Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study

Investigating Therapy for Non-High Risk Neuroblastoma in Young Patients

Recruiting
1 years or below
All
Phase N/A
1 Location

Brief description of study.

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Detailed description of study

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-high-Risk Neuroblastoma,neuroblastoma,cancer,oncology,pediatric,infant,kid,kids,child,children,baby,riley
  • Age: 1 years or below
  • Gender: All

Inclusion Criteria
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors

Updated on 19 Feb 2024. Study ID: 1410350695 (PHO-COG-FALLON-ANBL1232)

This study investigates how well therapy guided by response and biology-based risk factors works for treating young patients with non-high risk neuroblastoma. Neuroblastoma is a type of cancer that forms in certain types of nerve tissue and is most commonly found in children. The study aims to tailor treatment based on how the disease responds and the biological risk factors involved.

Participants will undergo specific procedures to assess the effectiveness of the therapy. These procedures may include imaging tests and other assessments to monitor the disease and the body's response to the treatment. The goal is to determine if adjusting therapy based on these factors can improve outcomes for young patients.

  • Who can participate: Children who are 12 months old at diagnosis with specific types of neuroblastoma can participate. They must have newly diagnosed non-amplified MYCN neuroblastoma or ganglioneuroblastoma. Patients with MYCN amplified tumors are not eligible.
  • Study details: Participants will receive therapy based on their response and biological risk factors. This means the treatment may change depending on how the disease is reacting and certain biological markers. There is no placebo used in this study.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here